With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight

When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention.

Tuesday, the Senate Health, Education, Labor and Pensions (HELP) Committee's hearing on Ozempic and Wegovy prices, which featured Novo Nordisk's CEO Lars Fruergaard Jørgensen as the sole witness, was no different.